Tokyo, Sept. 2 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062764) titled 'A study of whether initiating an oral SARS-CoV-2 antiviral (ensitrelvir, nirmatrelvir/ritonavir, or molnupiravir) on the day of outpatient COVID-19 diagnosis reduces newly recorded subacute post-COVID symptoms (impaired smell, impaired taste, fatigue, cough, appetite loss) during days 29-60 after diagnosis, using a Japanese claims database (target trial emulation)' on Sept. 1.
Study Type:
Observational
Primary Sponsor:
Institute - The University of Osaka, Graduate School of Medicine Faculty of Medicine
Condition:
Condition - COVID-19 (acute COVID-19 diagnosed in outpatient care). The outcome is subacute post-COVID...